Related Experiment Video
Updated: Apr 7, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.5K
Renal Denervation for Resistant Hypertension: Past, Present, and Future.
Christian Ott1, Roland E Schmieder
1Department of Nephrology and Hypertension, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany, christian.ott@uk-erlangen.de.
Current Hypertension Reports
|July 3, 2015
Summary
Renal denervation (RDN) shows promise for resistant hypertension, but early trials faced challenges. New research is exploring improved techniques and patient selection for better blood pressure control.
Area of Science:
- Cardiovascular medicine
- Interventional cardiology
- Hypertension management
Background:
- Renal sympathetic nerve activity plays a role in hypertension.
- Early studies suggested significant blood pressure reduction with renal denervation (RDN).
- The Symplicity HTN-3 trial reported no significant effect, raising concerns about RDN's efficacy.
Purpose of the Study:
- To re-evaluate the role of RDN in resistant hypertension.
- To address methodological issues from previous trials.
- To identify patient subgroups who may benefit most from RDN.
Main Methods:
- Focus on new randomized prospective clinical trials.
- Involves refined interventional approaches.
- Emphasizes improved patient selection criteria.
Main Results:
- Initial widespread adoption of RDN in Europe was based on promising but potentially flawed early data.
- The Symplicity HTN-3 trial highlighted significant methodological limitations.
- A resurgence of interest and new trials are underway in 2015.
Conclusions:
- Methodological issues and poor execution likely impacted prior RDN trial results.
- RDN may still hold potential as a rescue therapy for treatment-resistant hypertension.
- Future research will focus on optimized techniques and patient selection for RDN.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:22Heart Failure Drugs: Diuretics
1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K